Brainshuttle™ Launched in Hawaii! 

Novel Alzheimer’s Drug Trontinemab with Brainshuttle™ Technology

A new Alzheimer’s clinical study using the investigational drug trontinemab, engineered with Brainshuttle™ technology, is now accepting participants in Hawaii. This approach aims to achieve rapid amyloid clearance with a favourable safety and tolerability profile, including low rates of ARIA (Amyloid Related Imaging Abnormalities).

Background: Current Alzheimer’s Antibody Treatments

According to Roche, currently approved monoclonal antibodies such as Leqembi and donanemab have shown an ability to slow the decline of Alzheimer’s disease. However, the effects on disease progression are considered modest and are associated with potential side effects, most notably swelling or bleeding in the brain, known as ARIA (Amyloid Related Imaging Abnormalities).

What Is Trontinemab and Brainshuttle™ Technology?

Roche’s experimental Alzheimer’s disease drug trontinemab is an investigational Brainshuttle™ bispecific 2+1 amyloid-beta targeting monoclonal antibody. It is specifically engineered to enhance crossing of the blood–brain barrier via active TfR1-mediated transcytosis at the capillary level.

In the Phase Ib/IIa Brainshuttle™ Alzheimer’s disease study, trontinemab demonstrated rapid and robust amyloid plaque reduction at relatively low doses (1.8 and 3.6 mg/kg) compared with standard anti–Aβ monoclonal antibodies such as lecanemab and donanemab.

Promising Early Results

Preliminary results at the 3.6 mg/kg dose show:

• Further acceleration of amyloid plaque reduction
• Amyloid negativity in a majority of participants after just 12 weeks of treatment
• Sustained low ARIA incidence, with no ARIA-E or ARIA-H observed at 3.6 mg/kg so far

These findings support ongoing investigation of trontinemab in the Brainshuttle™ Alzheimer’s disease study.

Who Qualifies for the Study?

Individuals may qualify to participate in this study if they:

• Are between 50 and 90 years old
• Have early Alzheimer’s disease
• Have a Mini-Mental State Examination (MMSE) score > 21

Additional eligibility criteria will be reviewed by the study team.

Learn More or Enroll

For more information, please refer to official NIH clinical trial information or contact: Hawaii Memory Disorders Center & Alzheimer’s Research Unit
Phone: (808) 564-6141
Email: info@HawaiiNeuroscience.com